Article
Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
BioMed research international - 1 Jan 2013
Mu Xiaodong, Zhang Ye, Qu Xiujuan, Hou Kezuo, Kang Jian, Hu Xuejun, Liu Yunpeng
Abstract excerpt
Epidermal growth factor receptor (EGFR) is one of the most promising targets for non-small-cell lung cancer (NSCLC). Icotinib, a highly selective EGFR tyrosine kinase inhibitor (EGFR-TKI), has shown promising clinical efficacy and safety in patients with NSCLC. The exact molecular mechanism of icotinib remains unclear. In this study, we first investigated the antiproliferative effect of icotinib on NSCLC cells....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.